Mainboard · BSE and NSEDraft filed

ARAGEN LIFE SCIENCES LIMITED IPO: dates, price band, lot size, objects of the issue

Get updates on this IPO

Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.

Dates, allotment, listing and analyst views. Stop anytime.

By continuing you agree to the Terms and Privacy policy

Updated Sun 15 Nov 2026, 8:04 pm IST · Source: DRHP dated Wed 26 Aug 2026

Key facts

Price band
Not announced
Lot size
Not announced
Lot amount at the upper band
Not announced
Issue size at the upper band
Not announced
Fresh issue
₹800.00 crore
DRHP dated Wed 26 Aug 2026, page 83
Offer for sale
2,73,29,192 shares (Amount not stated in the draft)
DRHP dated Wed 26 Aug 2026, page 83
Bid dates
Not announced
Listing date
Not announced
Risk factors
93
DRHP dated Wed 26 Aug 2026, page 82
Proposed exchanges
BSE and NSE

Timeline (IST)

  1. Draft filedTue 1 Sep 2026 confirmedDRHP dated Wed 26 Aug 2026
  2. OpensDates to be announced
  3. ClosesDates to be announced
  4. AllotmentDates to be announced
  5. Refund and unblockDates to be announced
  6. ListingDates to be announced

Objects of the issue

ObjectAmount
Repayment and/or pre-payment, in part or full of certain borrowings availed by our Company and Material Subsidiaries₹385.00 crore
Capital expenditure to be incurred by the Company for purchase of new equipment and machinery for the facilities in Hyderabad₹154.00 crore
Capital expenditure to be incurred by one of our Material Subsidiaries, namely Aragen Biologics Private Limited for purchase of new equipment and machinery for the facility in Bengaluru, Karnataka^₹71.00 crore
General corporate purposes(1)Not stated in the draft
TotalNot stated in the draft

The offer for sale goes to the selling shareholders, not the company. DRHP dated Wed 26 Aug 2026, page 139

Company and promoters

As described in the DRHP

We are a fully integrated contract research, development and manufacturing organization (“CRDMO”) serving global innovator companies and emerging firms in the life sciences industry.

DRHP dated Wed 26 Aug 2026, page 239

Promoters

  • Reddy Investment Trust
  • Madhubani Investments Private Limited
  • 3 individual promoters

DRHP dated Wed 26 Aug 2026, page 319

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group59.44%Not stated in the DRHP
Public39.55%Not stated in the DRHP

DRHP dated Wed 26 Aug 2026, page 124

Financials (restated)

ItemMarch 31, 2026March 31, 2025March 31, 2024
Revenue from operations₹2,178.39 crore₹1,845.11 crore₹1,657.58 crore
Profit after tax₹257.64 crore₹180.38 crore₹160.10 crore
Net worth₹2,231.24 crore₹2,057.38 crore₹1,304.55 crore
Total borrowingsNot stated in the draftNot stated in the draftNot stated in the draft

DRHP dated Wed 26 Aug 2026, page 87

Who is selling in the offer for sale

Selling shareholderTypeShares offeredAmount at the upper band
Reddy Investment TrustOther18,63,354Not announced
Individual shareholderIndividual6,21,118Not announced
WSCPVIII (Singapore) Pte. Ltd.Company1,84,60,361Not announced
WSCPVIII EMP (Singapore) Pte. Ltd.Company33,23,006Not announced
Goldman Sachs Capital Holdings III Pte. Ltd.Company25,65,193Not announced
WSCPVIII Parallel Intermediary (Singapore) Pte. Ltd.Company4,96,160Not announced
Total offer for saleNot stated in the draft

DRHP dated Wed 26 Aug 2026, page 83

Peer comparison (as in the DRHP)

Name of CompanyFace Value (₹) Per ShareP/E (1)EPS (₹) BasicEPS (₹) DilutedNAV (₹) Per Equity Share (2)RoNW (%)(3)
Our Company*10[●]#11.9411.74107.4711.75
Sai Life Sciences Ltd180.0416.6316.43118.3815.13
Anthem Biosciences Ltd277.5810.5510.4354.3021.68
Syngene International Ltd1049.037.877.87122.816.62

Reproduced from the DRHP dated Wed 26 Aug 2026, page 164; InsightPier adds no figures

Risk factors

93 total
  1. The business depends on drug companies continuing to outsource research, and most revenue comes from contract research (DRHP page 31)
  2. Most revenue comes from customers outside India, mainly North America and Europe (DRHP page 32)
  3. A small group of key customers brings in a large share of revenue (DRHP page 33)
  4. Facilities face strict quality rules and regulator and customer inspections; failures could bring regulatory action (DRHP page 34)
  5. The company relies on skilled scientific staff and may struggle to hire or keep them (DRHP page 36)

All 93 risk factors, DRHP pages 31 to 82

Offer document

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts